Randomized Study on the Efficacy of Standard Versus Low Roxadustat Dose for Anemia in Patients on Peritoneal Dialysis

Article Urology & Nephrology

Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study

Steven Fishbane et al.

Summary: Roxadustat effectively increased hemoglobin levels and reduced the risk of red blood cell transfusion in non-dialysis-dependent CKD patients, with an adverse event profile similar to that of placebo.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

添加到收藏夹

Article Transplantation

Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)

Evgeny Shutov et al.

Summary: The study demonstrated that Roxadustat is more effective than placebo in treating anemia in patients with chronic kidney disease. The treatment group showed significantly higher Hb response rate and Hb change from baseline compared to the placebo group.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

添加到收藏夹

Article Transplantation

Roxadustat for anemia in patients with end-stage renal disease incident to dialysis

Robert Provenzano et al.

Summary: This study demonstrated the efficacy and safety of roxadustat in treating chronic kidney disease-related anemia. Roxadustat was shown to be as effective as epoetin alfa in correcting and maintaining hemoglobin levels, with comparable rates of adverse events.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

添加到收藏夹

Article Urology & Nephrology

Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD

Tadao Akizawa et al.

Summary: Roxadustat was shown to maintain hemoglobin levels within a specified range in non-dialysis chronic kidney disease patients and demonstrated noninferiority to darbepoetin alfa. The safety profiles observed in this study were consistent with previous studies conducted in this patient population.

KIDNEY INTERNATIONAL REPORTS (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat

Mei Tang et al.

Summary: The meta-analysis found that roxadustat can increase hemoglobin, transferrin, and TIBC levels, as well as regulate iron metabolism in CKD patients with renal anemia. However, it may also increase the incidence of serious treatment-emergent adverse events (TEAEs) in NDD-CKD patients.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Effects of Roxadustat on the Anemia and Iron Metabolism of Patients Undergoing Peritoneal Dialysis

Keiji Hirai et al.

Summary: The study showed that roxadustat may improve anemia and reduce serum ferritin and TSAT levels in peritoneal dialysis patients, with a correlation between serum potassium concentration and roxadustat dose.

FRONTIERS IN MEDICINE (2021)

添加到收藏夹

Article Hematology